Avencell AVC-201-01

The Allo-RevCAR01-T-CD123 drug is a combination of a cellular component (Allo-RevCAR01-T) with a recombinant antibody derivative (R-TM123), which together form the active drug. The cellular component Allo-RevCAR01-T consists of an allogeneic human T-cell genetically multi-edited and expressing a reversed, universal chimeric antigen receptor (RevCAR) presenting an extracellular peptide epitope (RevCAR epitope). R TM123 functions as a bridging module between Allo RevCAR01-T and a CD123-expressing target cancer cell by selectively binding the RevCAR epitope and CD123.

The drug Allo-RevCAR01-T-CD123 is a combination of a cellular component (Allo-RevCAR01-T) and a recombinant antibody derivative (R-TM123), which together form the active drug. The cellular component Allo-RevCAR01-T consists of an allogeneic human T cell that is genetically edited multiple times and expresses a reverse universal chimeric antigen receptor (RevCAR) presenting an extracellular peptide epitope (RevCAR epitope). R TM123 acts as a bridging module between Allo RevCAR01-T and a CD123-expressing target cancer cell by selectively binding the RevCAR epitope and CD123.

{ "short_title": "Avencell AVC-201-01", "data_mode": "900", "data_mode_number": "000002294", "official_title": "Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123 Consisting of Genetically Modified T cells Carrying Reverse Chimeric \r\nAntigen Receptors (Allo-RevCAR01-T) in Combination With CD123 Target Module (R-TM123) for the Treatment of Patients With Selected \r\nHematologic Malignancies Positive for CD123.", "accrual_state": "running", "therapeutic_value": "therapeutic", "therapieansatz_value": "palliativ", "therapieintervention_value": "not_applicable", "therapielinie_value": "first", "ctgov_number": "NCT05949125", "eudract_number": "2022-501797-19", "general_contact_email": "ectu@ukdd.de", "general_contact_phone": "+49 351-4587566", "hauptpruefer_dd_name": "Prof. Dr. med. habil Martin Wermke", "description_laie_de": "Das Medikament Allo-RevCAR01-T-CD123 ist eine Kombination aus einer zellul\u00e4ren Komponente (Allo-RevCAR01-T) und einem rekombinanten Antik\u00f6rperderivat (R-TM123), die zusammen das aktive Medikament bilden. Die zellul\u00e4re Komponente Allo-RevCAR01-T besteht aus einer allogenen humanen T-Zelle, die genetisch mehrfach editiert ist und einen reversen, universellen chim\u00e4ren Antigenrezeptor (RevCAR) exprimiert, der ein extrazellul\u00e4res Peptidepitop (RevCAR-Epitop) pr\u00e4sentiert. R TM123 fungiert als Br\u00fcckenmodul zwischen Allo RevCAR01-T und einer CD123-exprimierenden Zielkrebszelle, indem es das RevCAR-Epitop und CD123 selektiv bindet.", "description_laie_en": "The drug Allo-RevCAR01-T-CD123 is a combination of a cellular component (Allo-RevCAR01-T) and a recombinant antibody derivative (R-TM123), which together form the active drug. The cellular component Allo-RevCAR01-T consists of an allogeneic human T cell that is genetically edited multiple times and expresses a reverse universal chimeric antigen receptor (RevCAR) presenting an extracellular peptide epitope (RevCAR epitope). R TM123 acts as a bridging module between Allo RevCAR01-T and a CD123-expressing target cancer cell by selectively binding the RevCAR epitope and CD123.", "description_expert_de": "Das Medikament Allo-RevCAR01-T-CD123 ist eine Kombination aus einer zellul\u00e4ren Komponente (Allo-RevCAR01-T) und einem rekombinanten Antik\u00f6rperderivat (R-TM123), die zusammen das aktive Medikament bilden. Die zellul\u00e4re Komponente Allo-RevCAR01-T besteht aus einer allogenen humanen T-Zelle, die genetisch mehrfach editiert ist und einen reversen, universellen chim\u00e4ren Antigenrezeptor (RevCAR) exprimiert, der ein extrazellul\u00e4res Peptidepitop (RevCAR-Epitop) pr\u00e4sentiert. R TM123 fungiert als Br\u00fcckenmodul zwischen Allo RevCAR01-T und einer CD123-exprimierenden Zielkrebszelle, indem es das RevCAR-Epitop und CD123 selektiv bindet.", "description_expert_en": "The Allo-RevCAR01-T-CD123 drug is a combination of a cellular component (Allo-RevCAR01-T) with a recombinant antibody derivative (R-TM123), which together form the active drug. The cellular component Allo-RevCAR01-T consists of an allogeneic human T-cell genetically multi-edited and expressing a reversed, universal chimeric antigen receptor (RevCAR) presenting an extracellular peptide epitope (RevCAR epitope). R TM123 functions as a bridging module between Allo RevCAR01-T and a CD123-expressing target cancer cell by selectively binding the RevCAR epitope and CD123.", "rechtsgrundlage_value": "AMG", "phase_amg_value": "I", "main_cat_id": 4, "sub_cat_id": 30 }

Settings